Ifosfamide in advanced pancreatic cancer
- 1 January 1986
- journal article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 18 (S2) , S55-S56
- https://doi.org/10.1007/bf00647453
Abstract
Ifosfamide was studied in advanced pancreatic tumor at the National Cancer Institute, Cairo. Over five years, 25 patients received a daily dose of 1.8 g ifosfamide for five days, courses reported every 21 days. Complete remission was achieved in 1 patient and partial remission in 14 patients, an overall result of 60%, average duration of response being 12+ months. Mesna was used for uroprotection.Keywords
This publication has 1 reference indexed in Scilit:
- The integration of chemotherapy into a combined modality approach for cancer treatmentCancer Treatment Reviews, 1975